Updated Overall Survival in a Randomized Study Comparing Dacomitinib with Gefitinib as First-Line Treatment in Patients with Advanced Non-Small-Cell Lung Cancer and EGFR-Activating Mutations

被引：0
|
作者：
Tony S. Mok
Ying Cheng
Xiangdong Zhou
Ki Hyeong Lee
Kazuhiko Nakagawa
Seiji Niho
Alka Chawla
Rafael Rosell
Jesus Corral
Maria Rita Migliorino
Adam Pluzanski
Kay Noonan
Yiyun Tang
Malaika Pastel
Keith D. Wilner
Yi-Long Wu
机构：
[1] Chinese University of Hong Kong,State Key Laboratory of Translational Oncology, Department of Clinical Oncology
[2] Jilin Provincial Cancer Hospital,Chungbuk National University Hospital
[3] First Affiliated Hospital of Third Military Medical University,Pulmonary Oncology Unit
[4] Chungbuk National University College of Medicine,Guangdong Lung Cancer Institute
[5] Kindai University Hospital,undefined
[6] National Cancer Center Hospital East,undefined
[7] SFJ Pharmaceuticals®,undefined
[8] Catalan Institute of Oncology,undefined
[9] Hospital Universitario Virgen del Rocio,undefined
[10] San Camillo-Forlanini Hospital,undefined
[11] Maria Sklodowska-Curie National Research Institute of Oncology,undefined
[12] Pfizer Inc.,undefined
[13] Pfizer Oncology,undefined
[14] Pfizer Oncology,undefined
[15] Guangdong General Hospital and Guangdong Academy of Medical Sciences,undefined
来源：
Drugs | 2021年 / 81卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：257 / 266
页数：9
相关论文
共 50 条
  • [1] Updated Overall Survival in a Randomized Study Comparing Dacomitinib with Gefitinib as First-Line Treatment in Patients with Advanced Non-Small-Cell Lung Cancer and EGFR-Activating Mutations
    Mok, Tony S.
    Cheng, Ying
    Zhou, Xiangdong
    Lee, Ki Hyeong
    Nakagawa, Kazuhiko
    Niho, Seiji
    Chawla, Alka
    Rosell, Rafael
    Corral, Jesus
    Migliorino, Maria Rita
    Pluzanski, Adam
    Noonan, Kay
    Tang, Yiyun
    Pastel, Malaika
    Wilner, Keith D.
    Wu, Yi-Long
    [J]. DRUGS, 2021, 81 (02) : 257 - 266
  • [2] Improvement in Overall Survival in a Randomized Study That Compared Dacomitinib With Gefitinib in Patients With Advanced Non-Small-Cell Lung Cancer and EGFR-Activating Mutations
    Mok, Tony S.
    Cheng, Ying
    Zhou, Xiangdong
    Lee, Ki Hyeong
    Nakagawa, Kazuhiko
    Niho, Seiji
    Lee, Min
    Linke, Rolf
    Rosell, Rafael
    Corral, Jesus
    Migliorino, Maria Rita
    Pluzanski, Adam
    Sbar, Eric I.
    Wang, Tao
    White, Jane Liang
    Wu, Yi-Long
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (22) : 2244 - +
  • [3] Improvement in Overall Survival in a Randomized Study That Compared Dacomitinib With Gefitinib in Patients With Advanced Non-Small-Cell Lung Cancer and EGFR-Activating Mutations (vol 36, pg 2244, 2018)
    Mok, T. S.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (31) : 3725 - 3725
  • [4] First-Line Dacomitinib versus Gefitinib in Advanced Non-Small-Cell Lung Cancer with EGFR Mutation Subgroups
    Wu, Y.
    Cheng, Y.
    Zhou, X.
    Lee, K. H.
    Nakagawa, K.
    Niho, S.
    Tsuji, F.
    Rosell, R.
    Corral, J.
    Migliorino, M. R.
    Pluzanski, A.
    Linke, R.
    Sbar, E.
    Wang, T.
    Zhang, H.
    Mok, T.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1754 - S1754
  • [5] First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations
    Sequist, Lecia V.
    Martins, Renato G.
    Spigel, David
    Grunberg, Steven M.
    Spira, Alexander
    Jaenne, Pasi A.
    Joshi, Victoria A.
    McCollum, David
    Evans, Tracey L.
    Muzikansky, Alona
    Kuhlmann, Georgiana L.
    Han, Moon
    Goldberg, Jonathan S.
    Settleman, Jeffrey
    Iafrate, A. John
    Engelman, Jeffrey A.
    Haber, Daniel A.
    Johnson, Bruce E.
    Lynch, Thomas J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15) : 2442 - 2449
  • [6] Meta-Analysis of First-Line Therapies in Advanced Non-Small-Cell Lung Cancer Harboring EGFR-Activating Mutations
    Haaland, Benjamin
    Tan, Pui San
    de Castro, Gilberto, Jr.
    Lopes, Gilberto
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2014, 9 (06) : 805 - 811
  • [7] Evaluation of the Effect of Proton Pump Inhibitors on the Efficacy of Dacomitinib and Gefitinib in Patients with Advanced Non-Small Cell Lung Cancer and EGFR-Activating Mutations
    Jerry Li
    Dana Nickens
    Keith Wilner
    Weiwei Tan
    [J]. Oncology and Therapy, 2021, 9 : 525 - 539
  • [8] Evaluation of the Effect of Proton Pump Inhibitors on the Efficacy of Dacomitinib and Gefitinib in Patients with Advanced Non-Small Cell Lung Cancer and EGFR-Activating Mutations
    Li, Jerry
    Nickens, Dana
    Wilner, Keith
    Tan, Weiwei
    [J]. ONCOLOGY AND THERAPY, 2021, 9 (02) : 525 - 539
  • [9] First-line single agent treatment with gefitinib in patients with advanced non-small-cell lung cancer
    Yin Y.-M.
    Geng Y.-T.
    Shao Y.-F.
    Hu X.-L.
    Li W.
    Shu Y.-Q.
    Wang Z.-X.
    [J]. Journal of Experimental & Clinical Cancer Research, 29 (1)
  • [10] First-Line Single Agent Treatment With Gefitinib in Advanced Non-Small-Cell Lung Cancer Patients
    Yin, Yong-mei
    [J]. BIOMEDICINE & PHARMACOTHERAPY, 2009, 63 (05) : 325 - 325
12345